You just read:

NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks

News provided by

NGM Bio

Apr 14, 2018, 04:00 ET